This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary RNA Virus Infection Diagnostics Development
BioVenic offers veterinary RNA virus infection diagnostics development solutions for the accurate detection and identification of RNA viruses—including influenza, coronaviruses, retroviruses, and arboviruses—in companion, livestock, and wildlife animals. Our platform covers molecular methods such as PCR and sequencing for virus detection and subtyping, serological and molecular assays for differentiation of diverse RNA viruses, and detection of arthropod-borne viruses like West Nile virus, enabling timely identification of emerging strains. We support customized diagnostic development across sample types (swabs, blood, tissue) with target discovery, full method optimization, and validation services to deliver precise, actionable diagnostic tools.
Importance of Developing Veterinary RNA Virus Infection Diagnostics Solution▼
Veterinary RNA Virus Infection Diagnostics Development Services
BioVenic's dedicated team of scientists and experts specializes in developing and providing advanced veterinary RNA virus infection diagnostics development solution. We offer a comprehensive range of services to accurately detect and identify various RNA viruses affecting a wide range of animal species.
- We employ molecular methods like PCR and sequencing to detect and subtype influenza viruses that affect companion animals, livestock, and wildlife.
- With our advanced serological assays and molecular diagnostics, we can accurately detect and differentiate various RNA viruses that impact animals, including coronaviruses and retroviruses.
- With state-of-the-art laboratory equipment, we provide services for detecting and identifying arthropod-borne viruses such as West Nile virus.
- Our comprehensive approach allows for the timely identification of emerging strains and informs targeted prevention and control strategies.
Common RNA Viruses We Can Detect
BioVenic provides state-of-the-art diagnostic development solution that help customers to develop novel and accurate diagnostic assays that are able to detect and identify a wide range of veterinary RNA viruses, including positive-strand RNA viruses, double-stranded RNA viruses, negative-strand RNA viruses, and retroRNA viruses. The table below shows some of our detection capabilities. ▼
Our Service Flowchart
Sample Collection and Submission
Analysis and Testing
Laboratory Analysis
Data Interpretation and Reporting
Related Research
A multiplex reverse transcription-polymerase chain reaction (mRT-PCR) assay was developed for the simultaneous detection and differentiation of four potentially zoonotic swine RNA viruses: porcine sapovirus (SaV), encephalomyocarditis virus (EMCV), porcine rotavirus A (RVA), and porcine astrovirus (AstV). To establish the molecular diagnostic protocol, gene-specific primers targeting conserved regions were optimized under standardized thermal cycling and reaction parameters to yield distinct amplicon sizes without non-specific cross-reactivity against six non-target enteric swine pathogens. Using pooled recombinant plasmid standards containing the respective viral target sequences, the optimized assay demonstrated high analytical sensitivity with a lower limit of detection (LOD) of 2.5x10^3 copies per target virus. Diagnostic performance evaluated on 280 porcine fecal field samples identified both single and co-infections, yielding detection positivity rates of 24.6% for SaV, 17.5% for AstV, 5.0% for EMCV, and 4.3% for RVA. Overall, this multiplex assay offers a highly specific, sensitive, and cost-effective molecular framework for streamlined epidemiological surveillance and rapid clinical diagnosis of complex swine viral infections.
Fig. 1 RT-PCR optimization and assay specificity.1
Why Choose Us?
Tailored diagnostics development solutions
We create custom diagnostic solutions for RNA viruses in a variety of samples (swabs, blood, tissue, etc.).
Expertise in veterinary virology
We have a deep and extensive understanding of animal RNA viruses and develop diagnostic solutions for various RNA viruses for our customers.
Collaborative approach
To achieve precise and actionable results, our team works closely with clients to help discover targets that identify RNA pathogens and provide complete optimization services.
Case Study
BioVenic delivered a custom indirect ELISA to provide a reliable serological test for monitoring herd-level exposure and vaccine response to an emerging RNA virus in livestock through its one-stop diagnostics service—from selection of a conserved viral protein as the coating antigen, through assay design and optimization, to supply of a complete ready-to-use kit with validated reference panels. As shown in the figure, antibody levels in naturally infected and vaccinated animals rose clearly above the cut-off within the first week and peaked by days 21–28, while negative controls remained consistently low, giving veterinarians a clear, quantitative readout to distinguish exposed or vaccinated animals from naive ones.
Fig. 2 Serum Antibody Measured by ELISA
Frequently Asked Questions
Q1: What sample types are typically acceptable for custom RNA virus diagnostic assay development?
A: We accept various biological matrices, including serum, plasma, tissue homogenates, swab fluids, and oral fluids. Because RNA integrity is crucial, samples must be handled using appropriate RNA stabilization reagents and shipped under strict cold-chain conditions (e.g., dry ice). Prior to sending any clinical or experimental samples, please consult our technical support team to confirm specific sample volume, transport buffers, and prep instructions for your target virus.
Q2: What diagnostic assay platforms do you support for RNA virus detection?
A: Our development capabilities span molecular, immunological, and point-of-care platforms. We specialize in RT-qPCR, RT-LAMP, lateral flow assays (LFA), and antigen/antibody ELISAs tailored for veterinary medicine. Depending on your project requirements—such as target sensitivity, turnaround time, or field vs. laboratory use—we can customize the assay format. If you are uncertain which platform best fits your budget and target performance, our technical experts are available to evaluate your project needs.
Q3: How do you address the high mutation rates of RNA viruses during target design?
A: RNA viruses exhibit high genetic variability, which can compromise diagnostic sensitivity over time. For specific virus strains or newly emerging variants, we recommend discussing your target sequence data directly with our technical support staff.
Q4: What are the typical project timelines and deliverables for custom assay development?
A: Project timelines depends on the chosen technology platform, whether key reagents (such as specialized recombinant antigens or antibodies) need to be developed de novo, and the scope of validation required. Deliverables typically include optimized diagnostic protocols, validation reports, and prototype reagent kits or components. To receive a detailed timeline and a customized project proposal, please reach out to our technical support team.
When considering the creation of development solutions for veterinary RNA virus infection in vitro diagnostics, BioVenic emerges as the dependable and esteemed option. In the event of any queries or uncertainties, we wholeheartedly encourage you to contact us. Your questions hold significant importance, and we are dedicated to supplying the information you require.
Reference
- Werid, Gebremeskel Mamu, et al. "Development of a multiplex RT-PCR assay for simultaneous detection of four potential zoonotic swine RNA viruses." Veterinary Sciences 9.4 (2022): 176. https://doi.org/10.3390/vetsci9040176. Used under CC BY 4.0. Without modification.